Medicina Personalizada y Salud Mental

Investigación clínica en Reumatología, Nefrología, Enfermedades Raras, Depresión, Esquizofrenia, Hipertensión, Neurología, Reumatología, Reproducción, Cáncer, Cardiovascular.

Farmacología Clínica (Ensayos Clínicos, Farmacovigilancia, Concentraciones de Fármacos).

Farmacogenética.

Farmacología clínica.

Monitorización de fármacos.

Psicofarmacología.

Epidemiología y Farmacoepidemiología.

Farmacogenética Clínica y Medicina Personalizada.

Proyectos de investigación

SISTEMA DE MEDICINA PERSONALIZADA

GRUPO DE INVESTIGACIÓN CLÍNICA Y TRASLACIONAL EN FARMACOGENÉTICA

OPTIMIZACIÓN DEL USO DE MEDICAMENTOS EN POBLACIONES INDÍGENAS Y MESTIZAS IBEROAMERICANAS

BIOMARCADORES FARMACOGENÉTICOS Y RESPUESTA AL TRATAMIENTO FARMACOLÓGICO DE LA COVID-19

APOYO A ENSAYOS CLÍNICOS Y ESTUDIOS INDEPENDIENTES SOBRE LA COVID-19 EN EXTREMADURA

AYUDAS PARA PLATAFORMAS DE APOYO A LA INVESTIGACIÓN EN CIENCIA Y TECNOLOGÍA DE LA SALUD

IMPaCT-GENóMICA

CDTI-REALIZACIÓN DE LOS TRABAJO REFERENTES A TAREAS DIRECTOS E INDIRECTOS A2.1, A.2, A4.2 DEL PROYECTO QSALUD: FARMACOGENÉTICA CUÁNTICA APLICADA AL ENVEJECIMIENTO.

Planes Complementarios Comunidades Autónomas, Componente 17 de Plan de Recuperación, Transformación y Resiliencia, área de Biotecnología Aplicada a la Salud, Línea de actuación 2 (LA2) “Implementación y análisis de bases de datos en medicina de precisión”

AYUDA AL GRUPO DE INVESTIGACIÓN DENOMINADO "INVESTIGACIÓN CLÍNICA Y TRASLACIONAL EN FARMACOGENÉTICA"

Contratación técnico PROGRAMA INVESTIGO para desarrollo de proyecto “Estrategia de implementación clínica de Medicina Personalizada basada en la ascendencia para poblaciones latinoamericanas. (PerMed4LAT)”

EVALUACIÓN DE UNA PROPUESTA DE IMPLEMENTACIÓN DE FARMACOGENÉTICA EN EL SISTEMA NACIONAL DE SALUD PARA SALUD MENTAL Y CARDIOVASCULAR. BioFRaM22 * Fondo total consorcio 2.899.798 EUROS

Estrategia de implementación clínica de Medicina Personalizada basada en la ascendencia para poblaciones latinoamericanas. (PerMed4LAT).

Contratación de personal de apoyo a la investigación para el proyecto “VARIABILIDAD FARMACOGENÉTICA EN LA RESPUESTA AL USO MÉDICO Y ABUSO DE CANNABINOIDES [CANNAgEx]”

Publicaciones

Hot topic: Pharmacogenetic and Pharmacogenomics.

Increased use of second generation antipsychotic drugs in primary care: potencial relevance for hospitalizations in schizophrenia patients.

[Our experience in primary hyperaldosteronism].

Actualización del tratamiento con AINE en espondiloartritis.

Anterior cingulate activity in bulimia nervosa: a fMRI case study.

Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?

CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.

Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele.

Association between T102 and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs

Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.

Estudio farmacogenético del polimorfismo metabólico de debrisoquina (CYP2D6) en la población cubana en relación a la española. [Study of debrisoquine hydroxilation polymorphism (CYP2D6) in the Cuban population compared to Spaniards].

No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patient.

Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.

Clinical Implications of CYP2D6 Genetic Polimorphism during Treatment with Antisychotic Drugs.

Aripiprazole-induced Parkinsonism and its association with dopamine and serotonin receptor polymorphisms.

Ibero-American Program of Science and Technology for Development Program.

High risk of polydipsia and water intoxication in schizophrenia patients.

Development of a new genotyping assay for detection of the BDNF Val66Met polymorphism using melting-curve analysis.

CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.

[Telemedicine applied to Nephrology. Another form of consultation].

[Is it time to apply the new information and communication technologies to Nephrology?].

[Acute renal failure after intake of mushrooms: the orellanus syndrome].

[Hypertension high resolution consultation. A year of experience].

[Vancomycin dosing in hemodialysis patients].

Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis.

Inadequate iodine nutrition of pregnant women from Extremadura (Spain).

Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.

Relationship between CYP2C8 genotypes and diclofenac 5-hidroxylation in healthy Spanish volunteers.

Subtyping undergraduate women along dietary restraint and negative affect.

Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers.

Relevance of CYP2D6-1584>G polymorphism for thioridazine/mesoridazine plasma concentration ratio in psychiatric patients.

Pharmacogenomics and personalized medicine in clinical practice.

Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.

Relevance of CYP2D6 for risperidone pharmacokinetics, pharmacodynamics and adverse reactions.

High risk of lifetime history of suicide attempts among CYP2D6 polymorphism in patients with eating disorders.

CYP2C9 allele frequency differences between populations of Mexican-Tepehuano, and Spaniards.

[The Epidat program].

Specific eating disorder clusters based on social anxiety and novelty seeking.

Evaluating a newly developed pharmacogenetic array: screening in a Spanish population.

Influence of CYP2D6 deletion, multiplication, -1584C-->G, 31G-->A and 2988G-->a gene polymorphisms on dextromethorphan metabolism among mexican tepehuanos and mestizos.

[The current situation for vascular access in the province of Caceres].

[Results of applying the Scientific Technical Quality Programme and Constant Quality Improvement for peritoneal dialysis].

Economic burden of knee and hip osteoarthritis in Spain.

Subtyping eating disordered patients along drive for thinness and depression.

Predictors of early change in bulimia nervosa after a brief psychoeducational therapy.

ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study.

Medicina Personalizada.

Pharmacological compliance in the treatment of arterial hypertension. A review of studies published between 1975 and 2011.

Eating disorder symptoms and CYP2D6 variation in cuban healthy females: A report from the Ibero-American network of pharmacogenetics.

Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study.

Losartan hydroxylation phenotype in an Ecuadorian population: influence of CYP2C9 genetic polymorphism, habits and gender.

Development of a new HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hidroxylation phenotypes.

High- performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients

Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders.

CYP2D6 and the severity of suicide attempts.

CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population.

CYP2D6 Ultrarapid Metabolism and Suicide.

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans.

CYP2D6 polymorphism in patients with eating disorders.

Pasteurella canis peritonitis in a peritoneal dialysis patient.

Varicella zoster virus: complications in an ANCA-positive vasculitis.

Lifetime obesity in patients with eating disorders: increasing prevalence, clinical and personality correlates.

Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285.

Highlights from the latest articles in CYP2D6 activity and breast cancer outcomes during treatment with tamoxifen.

Impact of cytochrome P450 genes on suicide attempt and risk.

Influence of admixture components on CYP2C9*2 allele frequency in eight Indigenous populations from Northwest Mexico.

Pharmacogenetics of clinical response to risperidone.

Interethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations.

Assessing clinical and functional outcomes in a gene-environment interaction study in first episode of psychosis (PEPs).

Use of Pharmacogenetics in bioequivalence studies to reduce sample size: An example with mirtazapine and CYP2D6.

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitryptiline monotherapy treatment in major depressive patients.

CYP2D6 - 1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.

Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms.

CYP2D6 genetic polymorphism and psychiatric patients hospitalization period.

Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population.

Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications.

Membranous glomerulonephritis secondary to neoplasia. Different forms of presentation.

Cytochrome P450 genetic polymorphisms of Mexican indigenous populations.

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab inpatients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.

CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.

Effectiveness of a clinical practice intervention in early rheumatoid arthritis.

Evaluation of drug metabolizing enzyme hydroxylation phenotypes in Hispanic populations: the CEIBA cocktail.

Personality changes in bulimia nervosa after a cognitive behaviour therapy.

MDR-1 genotypes and quetiapine pharmacokinetics in healthy volunteers.

Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response

Present status and perspective of Pharmacogenetics in Mexico.

CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics- guided clinical trials.

Interethnic differences in the relevance of CYP2C9 genotype and environmental factors on diclofenac metabolism in Hispanics from Cuba and Spain.

CYP2D6 polymorphism, mental and personality disorders in suicide attempters.

The genetics of eating disorders.

Cognitive behaviour therapy response and dropout rate across purging and nonpurging bulimia nervosa and binge eating disorder: DSM-5 implications.

Etnic background and CYP2D6 genetic polymorphism in Costa Ricans.

Differences in cognitive behavioral therapy dropout rates between bulimia nervosa subtypes based on drive for thinness and depression.

Bernard Lerer: Recipient of the 2014 Inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics).

Building a Socio-Technical GPS for Global Personalized Medicine.

A rapid and simple LC-MS/MS method for the simultaneous evaluation of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 hydroxylation capacity.

Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers.

Liver enzyme abnormalities during antipsychotic treatment: a case report of risperidone-associated hepatotoxicity.

CYP2D6 gene polymorphisms and predicted phenotype in eight Indigenous groups from northwestern of Mexico.